Literature DB >> 14980905

The effects of a polymerized bovine-derived hemoglobin solution in a rabbit model of arterial thrombosis and bleeding.

Emmanuel Marret1, Philippe Bonnin, Elisabeth Mazoyer, Bruno Riou, Ted Jacobs, Pierre Coriat, Charles-Marc Samama.   

Abstract

UNLABELLED: Hemoglobin-based oxygen carriers (HBOCs) have been developed primarily for their oxygenating function and possible use as an alternative to red blood cells during surgery or after major trauma. However, their effect on hemostasis has not been studied extensively. We compared the effects on hemostasis of bovine-derived hemoglobin solution (HBOC-201) with gelatin solution and saline infusion in an experimental model of arterial thrombosis and bleeding. After anesthesia, the Folts model was constructed in 30 rabbits. The common carotid artery was exposed, and a 60% stenosis was induced. A compression injury of the artery was then produced, which triggered a series of cyclic episodes of thrombosis (cyclic flow reductions [CFRs]). After the number of baseline CFRs was counted, animals were assigned randomly to one of three groups (n = 10 each): saline (control), gelatin, or HBOC-201 solution. The effect of studied solutions was observed by recording the number of CFRs during another period and was compared with that of saline. Ear immersion bleeding time was recorded after each CFR period. Gelatin and HBOC-201 had similar effects, manifested by significantly decreased CFRs (from median of 7 to 1 and 6 to 1, respectively) and significantly lengthened bleeding time (from 88 to 98 s and 81 to 102 s, respectively; P < 0.05). Saline infusion had no significant effect on CFRs or bleeding time. HBOC-201 and gelatin had similar effects marked by a reduction in the arterial thrombosis rate and increased bleeding time in rabbits. IMPLICATIONS: In a rabbit thrombosis and hemorrhagic model, a polymerized bovine-derived hemoglobin solution and a gelatin solution infusion decreased arterial thrombosis and lengthened bleeding time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980905     DOI: 10.1213/01.ane.0000099366.73625.dd

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Biophysical properties and oxygenation potential of high-molecular-weight glutaraldehyde-polymerized human hemoglobins maintained in the tense and relaxed quaternary states.

Authors:  Ning Zhang; Yiping Jia; Guo Chen; Pedro Cabrales; Andre F Palmer
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

Review 2.  Blood substitutes: why haven't we been more successful?

Authors:  Abdu I Alayash
Journal:  Trends Biotechnol       Date:  2014-03-12       Impact factor: 19.536

3.  Comprehensive characterization of tense and relaxed quaternary state glutaraldehyde polymerized bovine hemoglobin as a function of cross-link density.

Authors:  Xiangming Gu; Crystal Bolden-Rush; Clayton T Cuddington; Donald A Belcher; Chintan Savla; Ivan S Pires; Andre F Palmer
Journal:  Biotechnol Bioeng       Date:  2020-06-12       Impact factor: 4.530

4.  Tangential flow filtration facilitated fractionation and PEGylation of low and high-molecular weight polymerized hemoglobins and their biophysical properties.

Authors:  Xiangming Gu; Chintan Savla; Andre F Palmer
Journal:  Biotechnol Bioeng       Date:  2021-10-26       Impact factor: 4.530

5.  Early Intervention in Ischemic Tissue with Oxygen Nanocarriers Enables Successful Implementation of Restorative Cell Therapies.

Authors:  Ludmila Diaz-Starokozheva; Devleena Das; Xiangming Gu; Jordan T Moore; Luke R Lemmerman; Ian Valerio; Heather M Powell; Natalia Higuita-Castro; Michael R Go; Andre F Palmer; Daniel Gallego-Perez
Journal:  Cell Mol Bioeng       Date:  2020-05-29       Impact factor: 2.321

Review 6.  New Applications of HBOC-201: A 25-Year Review of the Literature.

Authors:  Min Cao; Yong Zhao; Hongli He; Ruiming Yue; Lingai Pan; Huan Hu; Yingjie Ren; Qin Qin; Xueliang Yi; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.